Compare GSK plc (GSK) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs KKR & Co Inc — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while KKR & Co Inc trades at $102.4 (market cap $90.64B). The key difference: GSK plc and KKR & Co Inc are close in size by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | KKR | |
|---|---|---|
Market Cap | $101.34B | $90.64B |
Sector | Health | Financials |
52-Week High | $61.18 | $152.16 |
52-Week Low | $36.20 | $83.88 |
Enterprise Value | $121.95B | $16.16B |
Dividend Yield | 3.49% | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
KKR trades at $102.21, up 5.14% with a bullish technical outlook and strong analyst support. Recent earnings beat expectations in Q1 2026, and the firm is expanding through joint ventures in renewable energy and acquisitions like EDF Power Solutions. Cash flow improved to $1.78B in 2025, though revenue dipped to $19.21B. The stock is near its 52-week high, with RSI indicating potential overbought conditions.
Outlook is positive with a consensus price target of $122.71, but risks include volatile cash flows and high debt. Growth drivers are strategic expansions and strong institutional backing, yet investors should monitor execution on recent deals and macroeconomic impacts on asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
